Lupin Launches First Generic of Pred Forte in the United States

Global pharma major Lupin Limited (Lupin) today announced the launch of the first generic version of Pred Forte® (Prednisolone Acetate) Ophthalmic Suspension USP, 1% in the United States. Being the first generic to be approved and launched, the company is entitled to 180-day competitive generic therapy (CGT) exclusivity.

Prednisolone Acetate Ophthalmic Suspension USP, 1% is a generic equivalent of Pred Forte® Ophthalmic Suspension, 1% of AbbVie, Inc. and is indicated for the treatment of steroidresponsive inflammation of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe. Pred Forte® had estimated annual sales of USD 198 million in the U.S. (IQVIA MAT August 2024).

"The launch of Prednisolone Acetate Ophthalmic Suspension is a milestone and is aligned with our commitment to enhancing access to innovative, affordable and quality healthcare solutions," said Vinita Gupta, CEO, Lupin. "This will strengthen our ophthalmic portfolio and will benefit patients seeking effective treatment for steroid-responsive inflammation."

Shares of Lupin Limited was last trading in BSE at Rs. 2243.15 as compared to the previous close of Rs. 2223.60. The total number of shares traded during the day was 16400 in over 1502 trades.

The stock hit an intraday high of Rs. 2250.00 and intraday low of 2196.20. The net turnover during the day was Rs. 36457757.00.

Source : Equity Bulls

Keywords

Lupin INE326A01037 Pharmaceuticals GenericVersion PedForte PrednisoloneAcetate OphthalmicSuspension